MyoD1 Antibody, anti-human, REAfinity™
Synonyms: Myoblast determination protein 1, Class C basic helix-loop-helix protein 1, bHLHc1, Myogenic factor 3, MYF3, MYOD, Myf-3
RECOMBINANT
Clone:
REA1515 | RM369
Type of antibody:
Recombinant antibodies, Primary antibodies
Isotype:
recombinant human IgG1
Applications:
MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:

Related products for MyoD1 Antibody, anti-human, REAfinity™

MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
FFPE
Species tested:
human
Tissue used:
rhabdomyosarcoma
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-139-893
Testing grade:
** Qualified
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin embedded (FFPE) human rhabdomyosarcoma. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using MyoD1 Antibody, anti-human, APC (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application imageView details view details

Application imageView details view details
Specifications for MyoD1 Antibody, anti-human, REAfinity™
Overview

REA1515 recognizes the human MyoD1 (Myoblast determination protein 1), transcription factor and a member of the myogenic regulatory factor (MRF) family. It plays a role in the development and differentiation of skeletal muscle cells.. It activates its own transcription which may stabilize commitment to myogenesis. MyoD1 has also been implicated in other processes, such as muscle metabolism and even the development of certain cancers. It is a strong indicator for rhabdomyosarcoma and also be found in other rare tumor types.

Alternative names

Myoblast determination protein 1, Class C basic helix-loop-helix protein 1, bHLHc1, Myogenic factor 3, MYF3, MYOD, Myf-3

Detailed product information

Technical specifications

Clone
REA1515
Clonality
monoclonal
Isotype
recombinant human IgG1
Host
human cell line
Type of antibody
Recombinant antibodies, Primary antibodies
Species reactivity
human
Cross-reactivity
mouse, rat
Antigen
MyoD1
Distribution of antigen
satellite cells, other

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for MyoD1 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support